ReviewJournal of hematology & oncology2016
Emerging roles of Nrf2 signal in non-small cell lung cancer.
Review in Journal of hematology & oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.PloS one · 2020Pooled it
- The expression profile and clinic significance of the SIX family in non-small cell lung cancer.Journal of hematology & oncology · 2016Pooled it
- Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions.GeroScience · 2026Article
- Perinatal nicotine-induced neurotoxicity and behavioral alterations in newborn mice are associated with oxidative stress, inflammation and downregulated Nrf2/HO-1 signaling: protective role of Anethum graveolens.Journal of molecular histology · 2025Article
- Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography.Nature communications · 2024Article
- Clobetasol propionate, a Nrf-2 inhibitor, sensitizes human lung cancer cells to radiation-induced killing via mitochondrial ROS-dependent ferroptosis.Acta pharmacologica Sinica · 2024Article
- Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.Molecular biology reports · 2024Article
- Review
- The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance.International journal of molecular sciences · 2022Review
- An update of Nrf2 activators and inhibitors in cancer prevention/promotion.Cell communication and signaling : CCS · 2022Review
- E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.Cell communication and signaling : CCS · 2022Article
- Multi-omics analysis identifies distinct subtypes with clinical relevance in lung adenocarcinoma harboringJournal of Cancer · 2022Article
- Radiotracer stereochemistry affects substrate affinity and kinetics for improved imaging of system xTheranostics · 2022Article
- Role of NRF2 in Lung Cancer.Cells · 2021Review
- Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells.Scientific reports · 2021Article
- Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2.Translational lung cancer research · 2020Article
- Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells.Antioxidants (Basel, Switzerland) · 2020Article
- Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.Cell death & disease · 2020Review
- Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) causes considerable mortality in the world. Owing to molecular biological progress, treatments in adenocarcinoma have evolved revolutionarily while those in squamous lung cancer remain unsatisfied. Recent studies revealed high-frequency alteration of Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-like factor 2 (Keap1/Nrf2) pathway within squamous lung cancer, attracting researchers to focus on this particular pathway. In NSCLC patients, deregulated Nrf2 signal is recognized as a common feature at both DNA and protein level. Emerging associations between Nrf2 and other pathways have been elucidated. MicroRNA was also implicated in the regulation of Nrf2. Agents activating or antagonizing Nrf2 showed an effect in preclinical researches, reflecting different effects of Nrf2 during tumor initiation and progression. Prognostic evaluation demonstrated a negative impact of Nrf2 signal on NSCLC patients' survival. Considering the importance of Nrf2 signal in NSCLC, further studies are required in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.